CD133 promotes angiogenesis in hepatocellular carcinoma; thus, combining CD133 CAR-T cells with anti-angiogenic drugs effectively inhibit new blood vessel formation in tumors. The gene discussed is PROM1; the disease is hepatocellular carcinoma.